## Astrid Murumägi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6126707/publications.pdf Version: 2024-02-01

|          |                | 759233       | 794594         |
|----------|----------------|--------------|----------------|
| 21       | 1,159          | 12           | 19             |
| papers   | citations      | h-index      | g-index        |
|          |                |              |                |
|          |                |              |                |
|          |                |              |                |
| 21       | 21             | 21           | 2478           |
| all docs | docs citations | times ranked | citing authors |
|          |                |              |                |

| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory<br>Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1416-1429.  | 9.4  | 334       |
| 2  | Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.<br>Scientific Reports, 2014, 4, 5193.  | 3.3  | 243       |
| 3  | Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover<br>Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research, 2018, 24, 794-806.                                | 7.0  | 177       |
| 4  | Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. Bioinformatics, 2016, 32, i455-i463.   | 4.1  | 87        |
| 5  | Consistency in drug response profiling. Nature, 2016, 540, E5-E6.   | 27.8 | 76        |
| 6  | Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic<br>leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene, 2019, 38, 3288-3300.                 | 5.9  | 39        |
| 7  | Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death and Disease, 2020, 11, 790.  | 6.3  | 38        |
| 8  | Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma<br>Cell Lines for Novel Biomarkers of Drug Efficacy. Molecular Cancer Therapeutics, 2018, 17, 2060-2071.             | 4.1  | 33        |
| 9  | Targeting ROR1 identifies new treatment strategies in hematological cancers. Biochemical Society<br>Transactions, 2017, 45, 457-464.  | 3.4  | 28        |
| 10 | Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Advances, 2017, 1, 2257-2268.   | 5.2  | 25        |
| 11 | Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling. Oncotarget, 2016, 7, 37407-37419.   | 1.8  | 16        |
| 12 | Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. Molecular Oncology, 2017, 11, 1156-1171.                               | 4.6  | 15        |
| 13 | Anagrelide for Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 1676-1687.   | 7.0  | 14        |
| 14 | Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers, 2021, 13, 3727.  | 3.7  | 13        |
| 15 | STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer<br>drugs in patient-derived cancer cells. Translational Oncology, 2021, 14, 101027.                                  | 3.7  | 9         |
| 16 | KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia, 2020, 34,<br>2780-2784.   | 7.2  | 6         |
| 17 | High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Translational Oncology, 2022, 15, 101290.   | 3.7  | 4         |
| 18 | Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute<br>Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130,<br>854-854. | 1.4  | 1         |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex<br>Vivo Patient Cells with in Vitro Cell Lines. Blood, 2014, 124, 2163-2163.     | 1.4 | 1         |
| 20 | Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance<br>Testing and Genomic Profiling. Blood, 2013, 122, 482-482.                     | 1.4 | 0         |
| 21 | High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate<br>Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. Blood, 2013, 122, 2719-2719. | 1.4 | 0         |